Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.

Details

Serval ID
serval:BIB_4CA435908C3F
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
Journal
Lung cancer
Author(s)
Subbiah V., Paz-Ares L., Besse B., Moreno V., Peters S., Sala M.A., López-Vilariño J.A., Fernández C., Kahatt C., Alfaro V., Siguero M., Zeaiter A., Zaman K., López R., Ponce S., Boni V., Arrondeau J., Delord J.P., Martínez M., Wannesson L., Antón A., Valdivia J., Awada A., Kristeleit R., Olmedo M.E., Rubio M.J., Sarantopoulos J., Chawla S.P., Mosquera-Martinez J., D' Arcangelo M., Santoro A., Villalobos V.M., Sands J., Trigo J.
ISSN
1872-8332 (Electronic)
ISSN-L
0169-5002
Publication state
Published
Issued date
12/2020
Peer-reviewed
Oui
Volume
150
Pages
90-96
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
Publication Status: ppublish
Abstract
The National Comprehensive Cancer Network guidelines recommend re-challenge with the first-line treatment for relapsed small cell lung cancer (SCLC) with chemotherapy-free interval (CTFI)≥180 days. A phase II study (NCT02454972) showed remarkable antitumor activity in SCLC patients treated with lurbinectedin 3.2 mg/m <sup>2</sup> 1 -h intravenous infusion every 3 weeks as second-line therapy. We report results for the pre-planned subset of patients with CTFI ≥ 180 days.
Twenty patients aged ≥18 years with pathologically proven SCLC diagnosis, pretreated with only one prior platinum-containing line, no CNS metastases, and with CTFI ≥ 180 days were evaluated. The primary efficacy endpoint was the overall response rate (ORR) assessed by the Investigators according to RECIST v1.1.
ORR was 60.0 % (95 %CI, 36.1-86.9), with a median duration of response of 5.5 months (95 %CI, 2.9-11.2) and disease control rate of 95.0 % (95 %CI, 75.1-99.9). Median progression-free survival was 4.6 months (95 %CI, 2.6-7.3). With a censoring of 55.0 %, the median overall survival was 16.2 months (95 %CI, 9.6-upper level not reached). Of note, 60.9 % and 27.1 % of patients were alive at 1 and 2 years, respectively. The most common grade 3/4 adverse events and laboratory abnormalities were hematological disorders (neutropenia, 55.0 %; anemia; 10.0 % thrombocytopenia, 10.0 %), fatigue (10.0 %) and increased liver function tests (GGT, 10 %; ALT and AP, 5.0 % each). No febrile neutropenia was reported.
Lurbinectedin is an effective treatment for platinum-sensitive relapsed SCLC, especially in patients with CTFI ≥ 180 days, with acceptable safety and tolerability. These encouraging results suggest that lurbinectedin can be another valuable therapeutic option rather than platinum re-challenge.
Keywords
Chemotherapy-free interval, Lurbinectedin, NCCN guidelines, Platinum re-challenge
Pubmed
Web of science
Open Access
Yes
Create date
02/11/2020 13:20
Last modification date
14/01/2021 6:22
Usage data